Article Figures & Data
Figures
- Figure 1 AHR Agonistic Activity Is Decreased in Patients With RRMS
Human embryonic kidney cells (HEK293) were transfected with pGud-Luc and pTK-Renilla plasmids. One day after transfection, cells were incubated with human healthy control serums (control; n = 36) or serum from patients with relapsing-remitting MS (RRMS; n = 84). Luciferase activity was assessed after 24 hours. Values are means of technical duplicate measurements. Lines represent mean and error bars SEM. ****p < 0.0001 by the Student t test. AHR = aryl hydrocarbon receptor.
- Figure 2 AHR Ligand Levels Correlate With Disease Severity and Duration in Patients With RRMS
(A) HEK293 cells were transfected with AHR reporter and control plasmid (pGud-Luc and pTK-Renilla). One day after transfection, cells were incubated with human serum from healthy controls (control; n = 36) or serum from patients with relapse-remitting MS (RRMS; n = 84) with different disability levels as determined by Expanded Disability Status Scale (EDSS), where higher scores indicate increased disease severity. Luciferase activity was assessed after 24 hours. Values are means of technical duplicate measurements. Lines represent mean and error bars SEM. **p < 0.01, and ****p < 0.0001 by the Student t test. (B) Solid line shows linear regression with correlation of AHR agonistic activity and disease severity as determined by EDSS in patients with RRMS (RRMS; n = 84). Values are means of technical duplicate measurements. Numbers indicated R2 and p value of linear regression analysis. p < 0.05 is considered significant. (C) Solid line shows linear regression correlating agonistic activity with disease duration in patients with RRMS (RRMS; n = 84). Values are means of technical duplicate measurements. p < 0.05 is considered significant. (D) 3D plot analyses of EDSS scores (x-axis), disease duration (y-axis), and AHR ligand levels (z-axis) in patients with RRMS. AHR = aryl hydrocarbon receptor.
- Figure 3 AHR Agonistic Activity Is Decreased in the Progressive Form of MS
(A) AHR agonistic activity in serum samples of healthy controls (control; n = 36) and patients with secondary progressive MS (SPMS; n = 35) was assessed in duplicates using AHR ligand–sensitive luciferase assay. (B) AHR agonistic activity in serum samples of healthy controls (control; n = 36) and patients with primary progressive MS (PPMS; n = 41) was assessed in technical duplicates using an AHR ligand–sensitive luciferase assay. Values are means of technical duplicate measurements. Lines represent mean and error bars SEM. Significance levels were determined by the Student t test. ***p < 0.001 and ****p < 0.0001. AHR = aryl hydrocarbon receptor.
- Figure 4 Longitudinal Reduction of AHR Agonistic Activity Correlates With Increasing White Matter Atrophy and Lesion Load Volume in Individual Patients With RRMS
(A) Analysis of AHR agonistic activity in 13 individual patients in serial measurements. Solid line shows correlation of sample drawing year with AHR agonistic activity. (B) Analysis of white matter volume in 13 individual patients in serial cerebral MRIs. Solid line shows correlation of drawing year with relative white matter volume in each individual patient. (C) Analysis of lesion load volume change in 13 individual patients in serial cerebral MRIs. Group 1 (7 patients) and group 2 (3 patients) consist of patients with a stable AHR activity course and were compared with group 3 consisting of 3 patients with a decreasing AHR activity course over the years. Lines represent mean and error bars SEM. **p < 0.01 by 1-way analysis of variance followed by the Tukey post hoc test. AHR = aryl hydrocarbon receptor; ns = not significant; RRMS = relapsing-remitting MS.
Tables
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
